Innovation in cell and gene therapy depends on scientific breakthroughs as well as enabling technologies that address key challenges in delivery, safety, and development efficiency. At the ELRIG Cell and Gene Therapy 2026 conference, a number of emerging technology developers showcased solutions designed to overcome some of the most persistent bottlenecks in the field.

The cell and gene therapy landscape is evolving. Directly editing the genome or subcellular processes isn’t an aspirational dream anymore, but a potentially game-changing class of therapeutics for life-threatening and seriously debilitating diseases. Zeeks was fortunate enough to attend ELRIG’s Cell and Gene Therapy conference in Cambridge, hearing from the scientists developing cell and gene therapies about innovations in development across a plethora of diseases and therape

ELRIG is a scientific association that predominantly organises science conferences. It has become a hub for the drug discovery community, from academics to commercial partners and medicine developers, all with a mission to foster open access to modern research and innovation. As a company in the centre of the rapidly changing landscape of drug discovery, including cell and gene therapies, AI in medicine development, and the emerging geographies, we spoke with Sanj Kumar,